2014
DOI: 10.1136/jclinpath-2014-202735
|View full text |Cite|
|
Sign up to set email alerts
|

CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival

Abstract: AimsWe hypothesised that CD1d expression in renal cell carcinoma (RCC) may play a role in modifying the host immune response. Our aims were to investigate the expression of CD1d and to correlate this with histopathology and clinical outcomes in a cohort study of patients with RCC.MethodsGene expression and tissue microarray studies on a panel of RCC tissue were performed. Clinicopathological correlation was analysed using χ2/Fisher's exact test. Relapse-free survival, cancer-specific survival and overall survi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
22
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 35 publications
(22 citation statements)
references
References 28 publications
0
22
0
Order By: Relevance
“…In breast cancer cells, the down-regulation of CD1d leads to decreased iNKT-mediated cytotoxicity and metastatic progression (Hix et al 2011). However, in renal cell carcinoma patients, the expression of CD1b is associated with high relapse and poor prognosis (Chong et al 2015). The administration of retinoic acid and αGalCer (iNKT agonist) alone or the transfusion of αGalCer-loaded DCs reduces the tumor size and the number of metastatic foci in a mouse model of breast cancer by enhancing CD8 + T-cell cytotoxicity (Chen and Ross 2012;Gebremeskel et al 2015).…”
Section: Invariant Nk T (Inkt) Cellsmentioning
confidence: 99%
“…In breast cancer cells, the down-regulation of CD1d leads to decreased iNKT-mediated cytotoxicity and metastatic progression (Hix et al 2011). However, in renal cell carcinoma patients, the expression of CD1b is associated with high relapse and poor prognosis (Chong et al 2015). The administration of retinoic acid and αGalCer (iNKT agonist) alone or the transfusion of αGalCer-loaded DCs reduces the tumor size and the number of metastatic foci in a mouse model of breast cancer by enhancing CD8 + T-cell cytotoxicity (Chen and Ross 2012;Gebremeskel et al 2015).…”
Section: Invariant Nk T (Inkt) Cellsmentioning
confidence: 99%
“…All CD1 molecules can be found on various leukemia and lymphomas, although the exact expression pattern varies between patients ( 29 , 52 , 53 ). In addition, CD1d can be found on subsets of medulloblastoma, multiple myeloma, and renal cell carcinoma patients ( 54 56 ). Other cells in the tumor microenvironment that suppress anti-tumor immunity and/or promote tumor growth also express CD1 molecules.…”
Section: The Targetsmentioning
confidence: 99%
“…Clinical management options for metastatic RCC remain limited, despite its immunogenic potential compared with other tumours,34 35 37–41 and multiple ongoing clinical trials are investigating different pathways and molecules, including immune checkpoints 42 43. Although the Checkmate 025 trial failed to show any additional benefit for the PD-L1-positive expression subgroup of nivolumab single agent,19 44 the newly reported Checkmate 214 trial, which used nivolumab in combination with ipilimumab (anti-CTLA4, another immune checkpoint molecule) demonstrated more benefit to PD-L1-positive patients compared with PD-L1-negative patients 14.…”
Section: Discussionmentioning
confidence: 99%